AR121759A1 - Inhibidores de cd38 - Google Patents

Inhibidores de cd38

Info

Publication number
AR121759A1
AR121759A1 ARP210100889A ARP210100889A AR121759A1 AR 121759 A1 AR121759 A1 AR 121759A1 AR P210100889 A ARP210100889 A AR P210100889A AR P210100889 A ARP210100889 A AR P210100889A AR 121759 A1 AR121759 A1 AR 121759A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
haloalkyl
hydroxyalkyl
groups
Prior art date
Application number
ARP210100889A
Other languages
English (en)
Inventor
Santosh S Kularni
Bharat Lagu
Xinyuan Wu
Original Assignee
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge Inc filed Critical Mitobridge Inc
Publication of AR121759A1 publication Critical patent/AR121759A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un compuesto representado por la fórmula estructura (1), o una sal farmacéuticamente aceptable de este, en caracterizado por que: X¹ y X² son independientemente CH o N, siempre y cuando X¹ y X² no sean ambas CH; Cy es un cicloalquilo C₃₋₇ opcionalmente sustituido con un grupo oxo o con uno o dos grupos Rˣ, donde Rˣ es halógeno, un alquilo C₁₋₄, una haloalquilo C₁₋₄, un hidroxialquilo C₁₋₄, -NHSO₂C₁₋₄alquilo o -SO₂-alquilo C₁₋₄; R¹ es -H, -NRᵃRᵇ, halógeno, -CN, -C(=O)NH₂, -COOH, un alquilo C₁₋₄, un haloalquilo C₁₋₄, un hidroxialquilo C₁₋₄, un alquenilo C₂₋₄, un alcoxi C₁₋₄, un alcoxialquilo C₁₋₄, un alquiltio C₁₋₄, una alquilsulfona C₁₋₄, un alcoxialquiltio C₁₋₄, un haloalquiltio C₁₋₄, un haloalcoxi C₁₋₄, un cicloalquilo C₃₋₄ o un heteroarilo que contiene 5 miembros, donde el heteroarilo que contiene 5 miembros está opcionalmente sustituido con uno, dos o tres grupos alquilo C₁₋₄; R² es un heteroarilo de 5 miembros sustituido opcionalmente con uno, dos o tres deuterios o grupos alquilo C₁₋₄; Rᵈ es H, haloalquilo C₁₋₄, hidroxialquilo C₁₋₄ o alquilo C₁₋₄ sustituido opcionalmente con alcoxi C₁₋₄; Rᵃ y Rᵇ independientemente son -H o alquilo C₁₋₄; y n es 0 ó 1.
ARP210100889A 2020-04-07 2021-04-06 Inhibidores de cd38 AR121759A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202041015255 2020-04-07

Publications (1)

Publication Number Publication Date
AR121759A1 true AR121759A1 (es) 2022-07-06

Family

ID=75690672

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100889A AR121759A1 (es) 2020-04-07 2021-04-06 Inhibidores de cd38

Country Status (14)

Country Link
US (1) US20230158024A1 (es)
EP (1) EP4132919A1 (es)
JP (1) JP2023521694A (es)
KR (1) KR20230051425A (es)
CN (1) CN115697985A (es)
AR (1) AR121759A1 (es)
AU (1) AU2021251753A1 (es)
BR (1) BR112022020291A2 (es)
CA (1) CA3179589A1 (es)
CO (1) CO2022015874A2 (es)
IL (1) IL297128A (es)
MX (1) MX2022012638A (es)
TW (1) TW202204331A (es)
WO (1) WO2021207186A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022542396A (ja) 2019-07-31 2022-10-03 ライボン・セラピューティクス・インコーポレイテッド Ｃｄ３８の阻害剤としてのヘテロ二環式アミド
AR124718A1 (es) 2021-01-29 2023-04-26 Ribon Therapeutics Inc Quinolinas y azaquinolinas como inhibidores de cd38
AU2022310682A1 (en) * 2021-07-12 2024-01-25 Cytokinetics, Inc. Cd38 modulators and methods of use thereof
CN118317955A (zh) * 2021-11-09 2024-07-09 塞里文斯股份有限公司 作为cd38抑制剂的n-(4-氨基环己基)嘧啶-4-甲酰胺
WO2023098699A1 (en) * 2021-12-01 2023-06-08 Nanjing Immunophage Biotech Co., Ltd Compounds and their uses as cd38 inhibitors
WO2023235880A1 (en) * 2022-06-02 2023-12-07 Aeovian Pharmaceuticals, Inc. Cd38 modulators and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170090478A (ko) * 2014-12-03 2017-08-07 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Cd38 억제제 및 치료 방법
WO2017079195A1 (en) 2015-11-02 2017-05-11 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
US11304946B2 (en) * 2017-11-21 2022-04-19 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists

Also Published As

Publication number Publication date
MX2022012638A (es) 2023-01-04
CA3179589A1 (en) 2021-10-14
CN115697985A (zh) 2023-02-03
WO2021207186A1 (en) 2021-10-14
JP2023521694A (ja) 2023-05-25
EP4132919A1 (en) 2023-02-15
AU2021251753A1 (en) 2022-12-08
TW202204331A (zh) 2022-02-01
US20230158024A1 (en) 2023-05-25
KR20230051425A (ko) 2023-04-18
BR112022020291A2 (pt) 2022-12-06
CO2022015874A2 (es) 2022-11-18
IL297128A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
AR121759A1 (es) Inhibidores de cd38
AR114972A1 (es) Compuestos
AR120896A1 (es) COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
AR112797A1 (es) Inhibidores de kras g12c y métodos para utilizarlos
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
AR114950A1 (es) Compuestos de benzamida
AR099495A1 (es) Derivados de amida, antagonistas de orexina
AR112774A1 (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona
AR115662A2 (es) Derivados de piperidina
AR073706A1 (es) Inhibidores del virus de la hepatitis c
AR097866A1 (es) Derivados de 4-azaindol
AR056327A1 (es) Compuestos de nucleosidos para el tratamiento de infecciones virales
RS51365B (en) N-`(1-5-DIFENIL-1H-PIRAZOL-3-IL) DERIVATIVES SULFONAMIDE SA AFINITETOM ZA RECEPTOR CB1
ES2259113T3 (es) Inhibidores del factor xa y de otras serinproteasas implicadas en la cascada de coagulacion.
PE20212070A1 (es) Moduladores de trex1
AR117978A1 (es) Inhibidores de 15-pgdh
AR093758A1 (es) Inhibidores de aril lactama quinasa
AR090103A1 (es) Derivados ciclicos de diaminopirimidina
AR079108A1 (es) Metodos para el tratamiento del virus de la hepatitis c con compuestos de oxoacetamida
AR054737A1 (es) Piperidinas sustituidas pesticidas.
AR094122A1 (es) Compuestos triciclicos moduladores de la actividad de cftr
AR101798A1 (es) Quinolinas herbicidas
AR123084A1 (es) Compuestos de indano, preparación y uso terapéutico de los mismos
AR113931A1 (es) Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinas
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo